Viromed Medical AG (ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, announced that its multi-year research into the application of cold atmospheric plasma (CAP) in the lung has been successfully completed. The study data will now be submitted for publication in a renowned scientific journal. The research focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine, and confirmed the potential of cold plasma as a physical, non-pharmacological treatment for severe infectious lung diseases. Results showed a clearly defined therapeutic safety window and complete reduction of pathogenic germs in lung epithelial models.
An important component of the study was ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School. The isolated, ventilation- and perfusion-capable lung model used realistically reflects key physiological characteristics of the human lung, enabling reproducible investigations on vital organ tissue. Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: “By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems of the human body. It is particularly encouraging that we are no longer speaking only about preclinical evidence, but are already seeing first successful applications in patients in a university clinical setting.”
Based on these results, Viromed’s technology has already been used in a university setting for a severe pulmonary individual case in a human patient. Following ethics committee approval, a university hospital with a department specializing in lung and transplantation medicine treated a patient with lung transplant complications. The use of cold plasma was very successful, and treating physicians described the positive clinical course as exceptional. The hospital plans to publish the case soon, and further severely ill patients with high risk of fatal outcomes are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies face limitations from antimicrobial resistance, cold plasma’s physical mode of action offers a new therapeutic dimension, including prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use in operations for bacterial endocarditis before valve prosthesis implantation, or application in the thorax for bacterial pleural empyema. More information about Viromed Medical AG can be found at www.viromed-medical-ag.de. The original release is available at www.newmediawire.com.
